Halozyme Therapeutics (NASDAQ:HALO) Given New $105.00 Price Target at TD Cowen

Key Points

• TD Cowen raised Halozyme’s price target from $96 to $105 and maintained a “buy” rating. The consensus view is “Moderate Buy,” with an average target of $91.20.
• Halozyme reported a strong quarter, with EPS of $2.28 versus the $1.79 consensus and revenue up 47.7% year over year to $481 million. The company also raised its fiscal 2026 EPS guidance to $8.65–$9.00.
• Shares surged 20.2% to $103.12, near the 52-week high, following the results and analyst upgrades. While institutional ownership remains high at 97.79%, insiders have sold about $5.1 million of stock over the past quarter.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its price target increased by research analysts at TD Cowen from $96.00 to $105.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price objective would suggest a potential upside of 1.82% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Friday. Weiss Ratings upgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, May 16th. Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and set a $110.00 price target on the stock in a research report on Friday. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $91.20.

Halozyme Therapeutics Trading Up 20.2%

Shares of NASDAQ:HALO traded up $17.36 during mid-day trading on Friday, reaching $103.12. The stock had a trading volume of 7,632,976 shares, compared to its average volume of 1,834,638. The firm has a market cap of $12.23 billion, a PE ratio of 37.09, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85. The firm has a 50 day simple moving average of $75.74 and a two-hundred day simple moving average of $71.25. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. During the same period in the previous year, the firm earned $1.54 earnings per share. The company's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 72,477 shares of company stock valued at $5,102,643. 2.50% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Abel Hall LLC grew its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock valued at $216,000 after purchasing an additional 129 shares during the last quarter. StoneX Group Inc. grew its holdings in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after purchasing an additional 132 shares during the last quarter. Moran Wealth Management LLC raised its position in Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock worth $2,396,000 after purchasing an additional 151 shares during the period. Finally, Twin Capital Management Inc. raised its position in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings beat: Halozyme reported adjusted earnings of $2.28 per share, versus the $1.79-$1.82 consensus range, while revenue rose 48% year over year to $481 million, well above the roughly $402 million estimate. Royalty revenue increased 50% to $308 million, highlighting continued momentum in the company’s ENHANZE platform. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: The company now expects revenue of $1.835-$1.910 billion, royalty revenue of $1.220-$1.245 billion, adjusted EBITDA of $1.225-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the prior consensus estimate of $8.02, signaling management’s confidence in sustained growth. Halozyme Q2 Earnings Beat Estimates
• Positive Sentiment: Business development exceeded expectations: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, already surpassing its full-year goal of three. These agreements could expand future royalty and licensing revenue.
• Positive Sentiment: Analyst support improved: Leerink Partners upgraded HALO to “outperform” with a $110 target, while HC Wainwright raised its target to $115 and maintained a “buy” rating.
• Neutral Sentiment: Citizens JMP raised its target to $93 and kept a “market outperform” rating; Wells Fargo lifted its target to $95 but maintained an “equal weight” rating. Both targets remain below the current trading level, indicating some analyst caution after the rally.
• Negative Sentiment: With HALO trading near its 52-week high, valuation and profit-taking risks may limit additional near-term gains despite the strong fundamental update.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source